Fact CheckerSign in

NCT05413122RecruitingPhase 2/3

Evaluating Smoking Cessation Interventions for PWH in South Africa

Evaluating Smoking Cessation Interventions for PWH in South Africa: Efficacy, Implementation, and Cost-effectiveness

Source: ClinicalTrials.gov · Last updated 19 Oct 2026

Brief summary (registry, in English)

The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.

Status (registry)
Recruiting
Phase (registry)
Phase 2/3
Study type
Interventional
Enrollment
660 (estimated)
First submitted
3 Jun 2022
Start date
27 Nov 2023
Primary completion date
31 Aug 2027
Lead sponsor
Johns Hopkins University
Diseases
HIV
NCT number
NCT05413122

What you commit to

  • Study type: Interventional · Phase 2/3
  • Planned participants: 660
  • From 27 Nov 2023 to the primary completion date, 31 Aug 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Currently (within the previous 14 days) receiving or using smoking cessation counselling or pharmacotherapy, or

Other illness

  • are unable to participate due to severity of medical illness, guided by a Karnofsky score of ≤ 40, or
  • have a history of seizures, cancer, heart disease, stroke, myocardial infarction, stomach ulcers, kidney failure, or liver failure, or
  • have a history of adverse reactions to varenicline or nicotine patch, or

Other

  • have generalized eczema or psoriasis, or
  • have cognitive dysfunction or psychosis as defined by the Mini-International Neuropsychiatric Interview (M.I.N.I.), or
  • have suicide risk as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS), or
  • are pregnant, planning to become pregnant in the next four months, lactating, or are unwilling to use effective birth control, or
  • are not planning to continue to receive care at the clinic for the next 52 weeks, or
  • are a household member of a currently enrolled participant in this trial, or
  • In the opinion of the attending investigator are not a candidate for the clinical trail.

Who the study is looking for

  • ≥18 years of age, and
  • attend one of the selected study clinics, and
  • have a confirmed diagnosis of HIV (evidenced by one of: clinic or hospital prescription for combination antiretroviral therapy (ART), or a current ART medication pack that has the patient's name documented thereon) and
  • have been taking ART for at least three consecutive months or evidence of taking ART for four of the past six months (to ensure engagement in care at the recruitment clinic), and
  • are current tobacco smokers (smoked at least 100 cigarettes in the subject's lifetime, smoked at least one cigarette daily in the past 30 days, have exhaled breath carbon monoxide (CO) ≥ 7 parts per million (ppm), and have a positive urine cotinine test), and
  • either own or have household access to a mobile phone, and
  • provide written informed consent.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Perinatal HIV Research Unit (PHRU)
Coordinator of this site? Confirm its status
SowetoSouth AfricaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.